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October 14, 2008:1347–51As stated by Dr. Aradi and colleagues, stable angina or low-risk
cute coronary syndrome patients have a small risk of adverse
vents following PCI. However, reduced thrombotic events still
ccur in such patients. The clinical impact of clopidogrel in these
ow-risk patients is well established and therefore, the lack of
fficacy of the drug may be as critical as in other settings (2,3). In
ddition, the link between PR and recurrent ischemic events after
CI is demonstrated in stable patients similarly to unstable
atients (4). As pointed out by Dr. Aradi and colleagues, the
eri-intervention level of PR inhibition may be more important
han the time of clopidogrel loading. We believe that the teaching
f our study is the clinical impact of a tailored dose of clopidogrel
o obtain a sufficient degree of PR inhibition peri-intervention in
rder to decrease post-procedural thrombotic events. Accordingly,
he number of acute events is low and may offer the possibility of
ost-intervention adjustment (1 acute stent thrombosis). Finally,
he frequency of clopidogrel low response is by far less frequent in
table patients compared with unstable patients, which may
ccount for their reduced rate of events. Furthermore, the low
isk of thrombotic events after PCI may well be a limit to con-
uct specific studies on stable patients that would need a large
umber of patients to be properly powered. Finally, the low
umber of patients included in the present study prevents any
ubgroup analysis to assess the impact of LD adjustment in sta-
le patients.
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biquitin-Proteasome
ystem in the Atherosclerotic
laque Progression
n the May 27, 2008, issue of the Journal, Herrmann et al. (1)
resented atherosclerosis as a protein-quality disease caused by
he accumulation at the vascular level of unfolded/misfolded
roteins linking ubiquitin-proteasome system (UPS) activity to
therosclerotic plaque formation. Although the investigators
aised an interesting scientific concern in this review that the
oss of function for proteins is important in cellular and tissue
unctions, we believe that they present only one side of the dual
ole that the UPS has in vascular lesion formation and plaque
nstability. In our opinion, one should distinguish between the
nitial stage of the plaque formation in which tissue begins to
eact to damaging stimuli (e.g., cell stresses) and the late stage
f plaque characterized by progression of plaque toward desta-
ilization and rupture. In this context, it is conceivable that the
rst stage is characterized by deposition and accumulation of
roteins in cells and tissues when they are produced in large
mounts in response to a noxious stimulus. It is conceivable that
uring this transient stage, the UPS physiologically serves as a
ompensatory circuit acting to avoid low-quality protein aggre-
ations within the endothelium of the vessel walls. This
ypothesis is counteracted by the limited amount of evidence in
umans as well as by the conflicting translation of animal data
o humans. Plaque progression, however, occurs when the
nsufficiency of UPS to degrade the excess of damaged proteins
ecomes a persistently stressful condition for the endothelium.
his leads to progressive accumulation of ubiquitinated pro-
eins, autophagic death, and ultimately to plaque rupture
riggered by a local inflammatory process (2). It is well known
hat an inflammatory process may activate UPS (3), leading to
n overactivity of the system that in turn can develop a vicious
ircle in atherosclerotic vessels. It may further increase inflam-
atory activity through de novo synthesis of the nuclear factor
appa B, which in turn leads to further increments of oxidative
tress and consequently an increase of the ubiquitinated pro-
eins. Indeed, increased UPS activity in plaque macrophage as a
onsequence of the persistent stress may enhance the synthesis
f nuclear factor kappa B in the same cell, possibly representing
crucial step in the pathophysiology of atherosclerosis progres-
ion toward instability. Nevertheless, these are only hypotheses.
pecific clinical studies evaluating the effect of an intervention
o selectively modulate the UPS, in relation to the stage of
isease, are the only ones able to give a definite answer to the
uestion whether an increase and/or a decrease in UPS activity
ay be responsible for atherosclerosis progression.
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eply
e thank Dr. Di Filippo and colleagues for their comment on our
ecent article (1) that a loss of the function of the ubiquitin-
roteasome system may present only one aspect of its role in the
therosclerotic disease process. They outline that the ubiquitin-
roteasome system serves a compensatory role to prevent the
ggregation of low-quality proteins in the vascular wall in the
nitial disease stage. This function is lost in the more advanced
isease stages as the ubiquitin-proteasome system becomes insuf-
cient to degrade the excess amounts of damaged proteins,
educing cell and tissue viability and fostering progression of
therosclerosis. Then again, inflammation, which has been so
ightly linked to atherosclerosis, may activate the ubiquitin-
roteasome system, which in turn can increase inflammatory
ctivity through synthesis of nuclear factor kappa B (NFkB) and
he generation of substrates for the ubiquitin-proteasome system.
ia this positive feedback cycle, the ubiquitin-proteasome system
akes a more active, contributing role to the atherosclerotic disease
rocess.
The presented viewpoint of their letter is in fact well aligned
ith the conceptual theme of our article. In support of a possible
ompensatory role of the ubiquitin-proteasome system in the
nitial stage of atherosclerosis, we described pro-atherosclerotic
ffects of chronic proteasome inhibition in experimental hypercho-
esterolemia (2). Further confirmation should be given by futuretudies showing a vasoprotective effect of the stimulation of the
ystem. Also, there is a need for studies on the modulation of the
ystem in the more advanced disease stages to truly confirm its
ausal role. In this, we are in full agreement with Dr. Di Filippo
nd colleagues.
Regarding inflammation, the ubiquitin-proteasome system in-
eed takes center stage in the classical activation pathway of
FkB, and its inhibition is thought to contribute to the efficacy of
roteasome inhibitors in chemotherapy. However, proteasome-
ndependent NFkB activation can still occur through the nonclas-
ical activation pathways that are stimulated under conditions of
nhanced oxidative stress (3). This reconciles the possible contra-
iction of an insufficiency of the ubiquitin-proteasome system and
et increased NFkB activation in advanced atherosclerosis. Cer-
ainly, an unimpaired and even stimulated ubiquitin-proteasome
ystem can contribute further to NFkB activation and inflamma-
ion in the initial stage of atherosclerosis as we outlined. Thus, the
oints made by Dr. Dr Filippo and colleagues are well taken and
mphasize the nuances of the topic and the need for further studies
n this area.
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